Loading the section
Ozon Pharmaceuticals (OZPH): the company is profitable, net margin 19.5%; profit is not backed by cash, cash flow to profit −0.12×. Dividends are under pressure, yield 0.6%. The debt load is moderate, net debt / EBITDA 0.75×. Data as of 29 September 2026.
Answers to 4 of 4 questions
What share of revenue the company keeps as profit
Data as of 5 October 2026
Does the company pay dividends regularly and can it afford the payout
Data as of 29 September 2026
How large the company's debt is relative to its earnings
Data as of 5 October 2026
Is the company's profit backed by real cash
P/E · RAS · Price as of 31 March 2026
Based on the 2025 annual report, P/E is 24.25×. The valuation history is still too short to compare the share with its own past: observations: 2.
By report year
P/E
Observations with a similar valuation: 1 — too few to speak of a pattern.
A similar valuation means P/E within a quarter of the current value. Each year's price is taken the following spring, once the annual report is known; the price change runs between those dates of adjacent years and excludes dividends. The share count used is the current one. This describes the past and is not a forecast.
Dividends are under pressure, yield 0.6%. The last payout was RUB 0.49 per share.
The debt load is moderate, net debt / EBITDA 0.75×. Net debt is RUB 8.96 bn.
The company is profitable, net margin 19.5%. Net income is RUB 6.17 bn.
Based on the 2025 annual report, P/E is 24.25×. The valuation history is still too short to compare the share with its own past: observations: 2.
What date the figures on this page are as of
The analysis is built on the issuer's published financial statements and disclosures. It is information, not investment advice.
Data as of 5 October 2026
There is no forecast here: this page does not predict the price. It shows what happened after a similar valuation in the past. Observations with a similar valuation: 1 — too few to speak of a pattern. A similar valuation means P/E within a quarter of the current value. Each year's price is taken the following spring, once the annual report is known; the price change runs between those dates of adjacent years and excludes dividends. The share count used is the current one. This describes the past and is not a forecast.